Search by drug, manufacturer, or indication

Displaying 1011 - 1020 of 1165

Sylvant (siltuximab)

Status:

Concluded with an LOI

Manufacturer:

Janssen Inc.

Indication:

Multicentric Castleman's Disease (MCD)

Last updated September 30, 2016

Fabrazyme (agalsidase beta)

Status:

Concluded with an LOI

Manufacturer:

Sanofi Genzyme Canada

Indication:

Fabry Disease

Last updated September 30, 2016

Revlimid (lenalidomide)

Status:

Concluded with an LOI

Manufacturer:

Celgene Inc.

Indication:

Multiple Myeloma (newly diagnosed)

Last updated September 14, 2016

Esbriet (pirfenidone)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Pulmonary fibrosis (idiopathic, mild to moderate)

Last updated September 11, 2016

Ferriprox (deferiprone)

Status:

Concluded with an LOI

Manufacturer:

ApoPharm Inc.

Indication:

Transfusional iron overload due to thalassemia

Last updated September 7, 2016

Ofev (nintedanib)

Status:

Concluded with an LOI

Manufacturer:

Boehringer Ingelheim (Canada) Ltd.

Indication:

Idiopathic pulmonary fibrosis (IPF)

Last updated August 29, 2016

Rosiver (ivermectin)

Status:

Concluded without agreement

Manufacturer:

Galderma Canada Inc.

Indication:

Rosacea

Last updated August 26, 2016

Simponi SC (golimumab)

Status:

Concluded with an LOI

Manufacturer:

Janssen Inc.

Indication:

Ulcerative Colitis

Last updated August 12, 2016

Arnuity Ellipta (fluticasone furoate)

Status:

Concluded with an LOI

Manufacturer:

GlaxoSmithKline Inc.

Indication:

Asthma

Last updated August 8, 2016

Breo Ellipta (fluticasone furoate/vilanterol)

Status:

Concluded with an LOI

Manufacturer:

GlaxoSmithKline Inc.

Indication:

Asthma

Last updated July 11, 2016